How do I get compassionate use access for HER2-Positive Breast Cancer drugs not yet approved

Accessing Compassionate Use for HER2-Positive Breast Cancer Drugs

I appreciate this important question. Let me walk you through how compassionate use works for HER2-positive breast cancer, based on current clinical practice and regulatory pathways.

What Compassionate Use Actually Is

Compassionate use (also called "expanded access") allows patients to access investigational drugs—medications still being studied in clinical trials that haven't yet received FDA approval—when standard treatments aren't working or aren't available. According to resources from CancerPatientLab webinars on treatment access, this pathway exists specifically for serious, life-threatening conditions like advanced breast cancer.

The Clinical Reasoning Behind HER2-Positive Breast Cancer Access

For HER2-positive breast cancer specifically, there's strong clinical rationale for compassionate use consideration:

• HER2 is a well-understood target: Your cancer cells have too much of a protein called HER2 (human epidermal growth factor receptor 2), which drives cancer growth
• Multiple approved options exist: Drugs like trastuzumab (Herceptin), pertuzumab (Perjeta), and trastuzumab deruxtecan (Enhertu) are already FDA-approved for HER2-positive disease
• New drugs in development: Newer HER2-targeted therapies are in clinical trials and may be accessible through compassionate use if you've exhausted standard options

How to Actually Access Compassionate Use

Here's the practical step-by-step process:

Step 1: Establish Medical Necessity

Your oncologist must document that:

• You have HER2-positive breast cancer (confirmed by testing)
• You've already tried standard-of-care treatments OR they're not appropriate for your situation
• You're healthy enough to tolerate treatment (you must be able to get out of bed at least half the day)
• No other approved options are suitable for your specific case

Step 2: Identify the Drug

Work with your medical team to identify which investigational drug might help. This could involve:

• Reviewing clinical trial databases (clinicaltrials.gov)
• Consulting with your oncologist about drugs in development
• Working with patient advocacy organizations that track emerging therapies

Step 3: Contact the Drug Manufacturer

Your physician (not you directly) must request compassionate use from the pharmaceutical company developing the drug. According to CancerPatientLab resources on treatment access, this typically involves:

• The drug company reviewing your medical case
• Determining if you meet their criteria
• Deciding whether they'll provide the drug

Important timing note: According to the webinars, some organizations like Anova can get compassionate use requests approved in as little as 2 hours, though this varies by company.

Step 4: FDA Approval (if needed)

If the drug company agrees, they may need to request FDA permission. The FDA evaluates:

• Your medical necessity
• The drug's safety profile
• Whether there's reasonable evidence it might help

Reality check: According to CancerPatientLab webinars, FDA responses can take weeks or months, and approval isn't guaranteed. The FDA sometimes denies requests if they feel there isn't enough evidence—even when doctors believe the treatment could help.

Step 5: Insurance and Cost

This is often the biggest barrier. According to the webinars:

• Insurance companies may refuse to pay for off-label or investigational drugs
• Some pharmaceutical companies provide drugs free through patient assistance programs
• Your hospital/clinic may absorb costs
• You might need to pay out-of-pocket (which can be thousands of dollars monthly)

Specific Resources That Can Help

Patient Assistance Organizations (mentioned in CancerPatientLab resources):

• Anova - specializes in compassionate use access and can work with manufacturers
• Cancer Commons - helps match patients with treatment options
• xCures - focuses on personalized treatment access
• Patient assistance programs from drug manufacturers (like Merck's Keytruda program)

These organizations can:

• Help your doctor navigate the request process
• Advocate with insurance companies
• Sometimes expedite approvals
• Connect you with "pioneering prescribers" (doctors experienced with off-label/compassionate use)

Questions to Ask Your Oncologist

To move this forward, bring these specific questions to your next appointment:

1. "Based on my HER2-positive breast cancer and treatment history, are there investigational HER2-targeted drugs you think might help me?"

2. "Which drug companies should we contact about compassionate use access, and what's your timeline for making that request?"

3. "What's your experience with compassionate use requests? How long did previous requests take?"

4. "If we identify a drug, will you help navigate insurance approval, or should I contact a patient advocacy organization like Anova or Cancer Commons?"

5. "Are there clinical trials I should consider instead of or alongside compassionate use?" (Trials sometimes provide faster access and more monitoring)

6. "What are the realistic costs, and does the manufacturer have a patient assistance program?"

Important Realities to Understand

According to CancerPatientLab webinars on treatment access:

• It's not automatic: Just because a drug exists doesn't mean you'll get access
• Timing matters: Delays can be critical with aggressive cancers
• Bias toward standard care: Some doctors and insurance companies prefer proven treatments over experimental ones, even when experimental options might help
• You need an advocate: Having your doctor actively pushing for access, or working with organizations like Anova, significantly improves chances
• Documentation is key: The more evidence your doctor provides about why this specific drug might help YOUR specific cancer, the better

The Bottom Line

Compassionate use is a real pathway for HER2-positive breast cancer patients, but it requires:

1. A proactive oncologist willing to advocate for you
2. Clear medical documentation of need
3. Persistence navigating insurance and regulatory systems
4. Often, help from patient advocacy organizations

Don't wait passively—bring this conversation to your oncology team now, especially if you're running out of standard options.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.